Leading CRAC Channel Platform Company Delivering Drug Candidates For Inflammatory Diseases
CRAC Channel Technology
Calcium release-activated calcium channels, or CRAC channels, are responsible for replenishing the calcium stores inside many cell types. Since calcium is an important regulator of multiple biological functions, CRAC channel activation controls several of these functions including inflammation, vascular permeability and cell death.
Auxora Pipeline
CalciMedica is advancing their lead product candidate AuxoraTM for the treatment of acute inflammatory conditions such as acute pancreatitis and COVID-19 pneumonia.
News
CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial
Reduction in time to recovery through day 60 in patients with moderate and severe respiratory failure (primary endpoint analysis) Statistically significant reduction in time to …
CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways
Data provides further evidence of the broad potential for CRAC channel inhibitors to benefit patients across multiple disease areas involving the lungs LA JOLLA, Calif., …